HOPO Therapeutics Analysis: $228M Raised
What is HOPO Therapeutics?
Oral chelators for heavy metal poisoning
Location
San Francisco Bay Area, United States
Employees
11-50
Founded
2020
Product Features & Capabilities
- Oral chelating agents for lead, mercury, uranium, and plutonium poisoning
- Radioligand therapy for targeted delivery
- Phase 1 clinical trial of HOPO 14-1
Use Cases
Treat patients exposed to uranium and plutonium in nuclear incidents; Manage lead poisoning in children and women; Provide oral therapy for environmental heavy metal exposure; Support radiological hazard response in emergency settings; Enable targeted delivery of radioisotopes in oncology
Other Considerations
Awarded $226 million BARDA contract; Jointly awarded $1.78M ARPA-E grant; Conducting Phase 1 clinical trial of HOPO 14-1; Backed by U.S. government funding and partnerships; World-class expertise in heavy metal chemistry from Lawrence Berkeley National Laboratory
See something that needs updating? Suggest edits to this profile.